Payment overview · 2025
General Payments
$858.43
21 reported records · 10 companies
Healthcare provider profile · identity verified
Derek Lewis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1407810641
Verified facts
What the public records show
CMS Open Payments records show Derek Lewis, M.D. received $858.43 in general payments during 2025 across 21 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 62.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $535.06 | 62.3% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $136.98 | 16.0% | 7 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $67.67 | 7.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.59 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.96 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.20 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.72 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.38 | 1.7% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $14.10 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.77 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $607.86 | 20 |
| Travel and Lodging | $250.57 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $136.98 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 801 | 295 |
| Atorvastatin Calcium | Atorvastatin Calcium | 769 | 285 |
| Gabapentin | Gabapentin | 492 | 170 |
| Losartan Potassium | Losartan Potassium | 485 | 181 |
| Metoprolol Tartrate | Metoprolol Tartrate | 422 | 149 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 416 | 144 |
| Simvastatin | Simvastatin | 400 | 138 |
| Metformin Hcl | Metformin Hcl | 361 | 125 |
| Diclofenac Sodium | Diclofenac Sodium | 321 | 156 |
| Omeprazole | Omeprazole | 307 | 115 |
| Ozempic | Semaglutide | 283 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 242 | 99 |
| Furosemide | Furosemide | 236 | 94 |
| Trazodone Hcl | Trazodone Hcl | 222 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 89 |
| Glimepiride | Glimepiride | 211 | 73 |
| Ibuprofen | Ibuprofen | 190 | 83 |
| Clonidine Hcl | Clonidine Hcl | 187 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 172 | 80 |
| Carvedilol | Carvedilol | 169 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 160 | 49 |
| Sertraline Hcl | Sertraline Hcl | 153 | 60 |
| Nifedipine Er | Nifedipine | 148 | 58 |
| Lisinopril | Lisinopril | 144 | 56 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 140 | 51 |
| Eliquis | Apixaban | 135 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 129 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 51 |
| Potassium Chloride | Potassium Chloride | 123 | 51 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 40 |
| Azithromycin | Azithromycin | 97 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 48 |
| Meloxicam | Meloxicam | 94 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 30 |
| Methylprednisolone | Methylprednisolone | 82 | 72 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 47 |
| Estradiol | Estradiol | 79 | 27 |
| Allopurinol | Allopurinol | 76 | 29 |
| Methotrexate | Methotrexate Sodium | 76 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 34 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 36 |
| Famotidine | Famotidine | 66 | 27 |
| Glipizide | Glipizide | 61 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 20 |
| Jardiance | Empagliflozin | 55 | 20 |
| Fluconazole | Fluconazole | 53 | 35 |
| Levemir Flexpen | Insulin Detemir | 52 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 23 |
| Valsartan | Valsartan | 52 | 22 |
| Sucralfate | Sucralfate | 51 | 23 |
| Cephalexin | Cephalexin | 50 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 17 |
| Entresto | Sacubitril/Valsartan | 49 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 17 |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 48 | 45 |
| Prednisone | Prednisone | 48 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 24 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 47 | 17 |
| Metronidazole | Metronidazole | 47 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Labetalol Hcl | Labetalol Hcl | 45 | 21 |
| Naproxen | Naproxen | 45 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 23 |
| Linzess | Linaclotide | 44 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 18 |
| Levetiracetam | Levetiracetam | 41 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 15 |
| Amoxicillin | Amoxicillin | 40 | 32 |
| Montelukast Sodium | Montelukast Sodium | 40 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Olanzapine | Olanzapine | 37 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 21 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | 21 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 32 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 12 |
| Novolog Flexpen | Insulin Aspart | 30 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Metformin Hcl Er | Metformin Hcl | 29 | 14 |
| Methimazole | Methimazole | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 18 |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 15 |
| Topiramate | Topiramate | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Atenolol | Atenolol | 25 | 11 |
| Epinephrine | Epinephrine | 24 | 20 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | 11 |
| Colchicine | Colchicine | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | 12 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 20 | 15 |
| Risperidone | Risperidone | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | 11 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 11 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $858.43 · 21 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, CAPLYTA, Dexcom G6 Transmitter, MOUNJARO, Senza, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error